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http://www.biomedcentral.com/1471-2261/14/128RESEARCH ARTICLE Open AccessUtility of NT-proBNP as a rule-out test for left
ventricular dysfunction in very old people with
limiting dyspnoea: the Newcastle 85+ Study
Joanna Collerton1*, Andrew Kingston1, Fahad Yousaf1, Karen Davies1, Antoinette Kenny2, Dermot Neely3,
Carmen Martin-Ruiz1, Guy MacGowan2,4, Louise Robinson1,5, Thomas BL Kirkwood1 and Bernard Keavney4,6Abstract
Background: Guidelines advocate using B-type natriuretic peptides in the diagnostic work-up of suspected heart
failure (HF). Their main role is to limit echocardiography rates by ruling out HF/LV dysfunction where peptide level
is low. Recommended rule-out cut points vary between guidelines. The utility of B-type natriuretic peptides in the
very old (85+) requires further investigation, with optimal cut points yet to be established. We examined NT-proBNP's
utility, alone and in combination with history of myocardial infarction (MI), as a rule-out test for LV dysfunction in very
old people with limiting dyspnoea.
Methods: Design: Cross-sectional analysis.
Setting: Population-based sample; North-East England.
Participants: 155 people (aged 87-89) with limiting dyspnoea.
Measures: Dyspnoea assessed by questionnaire. Domiciliary echocardiography performed; LV systolic/diastolic function
graded. NT-proBNP measured (Roche Diagnostics). Receiver operating characteristic analyses examined NT-proBNP's
diagnostic accuracy for LV dysfunction.
Results: AUC for LVEF less than or equal to 50% was poor (0.58, 95% CI 0.49-0.65), but good for LVEF less than or equal
to 40% (0.80, 95% CI 0.73-0.86). At ESC cut point (125ng/l), few cases of systolic dysfunction were missed (NPV 94-100%,
depending on severity), but echocardiography (88%) and false positive rates (56-81 per 100 screened) were high. At NICE
cut point (400ng/l), echocardiography (51%) and false positive rates (33-45) were lower; exclusionary performance was
good for LVEF less than or equal to 40% (1 case missed per 100 screened, 15% of cases; NPV 97%), but poor for
LVEF less than or equal to 50% (16 cases missed per 100 screened, 45% of cases; NPV 68%). Incorporating isolated
moderate/severe diastolic dysfunction into target condition increased the proportion of cases missed (lower NPV),
whilst improving case detection. Incorporating MI history as an additional referral prompt slightly reduced the number
of cases missed at expense of higher echocardiography and false positive rates.
Conclusions: High echocardiography rates and poor exclusionary performance for mild degrees of systolic dysfunction
and for diastolic dysfunction limit NT-proBNP's utility as a rule-out test for LV dysfunction in very old people with
limiting dyspnoea. Incorporating MI history as an additional echocardiography prompt yields no overall benefit
compared to using NT-proBNP level alone.
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The very old (aged 85+), the most rapidly expanding age
group worldwide, [1] comprise an increasing fraction of
heart failure (HF) patients [2]. Early and accurate diag-
nosis is important as effective therapies are well estab-
lished for HF with reduced left ventricular (LV) ejection
fraction (HF-REF). Furthermore, there is increasing em-
phasis on identifying asymptomatic LV systolic dysfunc-
tion and preventing or delaying its progression to HF
[3]. In older people HF diagnosis is particularly challen-
ging due to atypical clinical presentations, [4] coupled
with high levels of co-morbidity [2] which can both mimic
and mask the presentation of HF. Echocardiography, the
diagnostic test of choice, is expensive with limited access
in many healthcare systems, [5] particularly for older
people [6].
The B-type natriuretic peptides, BNP and NT-proBNP,
offer a less expensive and more accessible diagnostic test
for HF and LV dysfunction. Clinical guidelines advocate
their use in the diagnostic work-up of suspected HF to
limit the number of potential cases requiring echocardi-
ography, by ruling out the condition where natriuretic
peptide level is low, although recommended rule-out cut
points vary between guidelines [7,8]. A raised natriuretic
peptide level is insufficiently specific to rule in a diagno-
sis, [9] with echocardiography required for further evalu-
ation. The utility of B-type natriuretic peptides in the
very old requires further investigation, and the optimal
exclusionary cut points for this age group remain to be
established. Natriuretic peptide levels rise with age in
non-diseased individuals, [10] and with many age-related
cardiac and non-cardiac morbidities [11]. Furthermore,
their diagnostic accuracy is poorer in HF with preserved
ejection fraction (HF-PEF), [12] which underlies around
50% of HF in people over the age of 70 [13].
We previously reported high prevalence of LV systolic
and diastolic dysfunction in the very old, most cases be-
ing both symptomatic and undiagnosed [14]. We here
report a prospective evaluation of the utility of NT-
proBNP - alone and in combination with history of myo-
cardial infarction (MI) [as per UK National Institute for
Health and Care Excellence (NICE) Chronic HF Diag-
nostic Algorithm [7]] – as a rule-out test for LV systolic
and diastolic dysfunction in very old people with limiting
dyspnoea. Data came from the Newcastle 85+ Study, a
population-based longitudinal study of health and ageing
in the very old [15].
Methods
Participants
The recruitment strategy for the Newcastle 85+ Study
has been reported [15]. In brief, people living in Newcas-
tle or North Tyneside (North-East England) were re-
cruited at age 85 through general practice patient lists;those living in institutions and the cognitively impaired
were included. Participants were asked to undergo a car-
diac phenotyping examination during their 18 or 36 month
follow-up (see Supplementary appendix in Additional file
1) [14]. For this analysis, we focused on those participants
who reported limiting dyspnoea, identified using a nurse-
administered questionnaire. Participants were assigned to
three categories: limiting dyspnoea; no limiting dyspnoea;
or unclassifiable. Limiting dyspnoea indicated a clinical
suspicion of HF. We did not evaluate symptoms such
as orthopnoea, paroxysmal nocturnal dyspnoea, ankle
oedema and fatigue; whilst some have higher specifi-
city for HF than dyspnoea, all lack sensitivity [9]. Clas-
sical signs of HF were not evaluated being difficult to
elicit in older people and lacking both sensitivity and
specificity [9].
Echocardiographic determination of LV systolic and
diastolic dysfunction
Echocardiography was conducted in the home setting
(own or care home) by one experienced echocardiologist
who interpreted all scans. M-mode, two dimensional (2-D)
and Doppler echocardiography - including tissue Doppler
measurement of LV long axis velocities - was performed
using a portable instrument (Vivid i BT06 with i2 perform-
ance package; GE Healthcare, USA). A standardised
protocol was followed, conforming to guidelines from
the American and British Societies of Echocardiog-
raphy [16,17] (Additional file 1: Table S1).
NT-proBNP measurement
Plasma samples for NT-proBNP measurement were ali-
quoted on day of collection and stored at -80°C. NT-
proBNP was measured by an electrochemiluminescent
sandwich immunoassay using the Modular Analytics E170
system (Roche Diagnostics, Lewes, UK). The between-
batch coefficient of variation is 1.5-3.5% from 122-
4322ng/l, with an analytical range of 5-35000ng/l.
The laboratory performing the NT-proBNP assay and
the echocardiologist were blinded to the echocardio-
graphic and NT-proBNP data respectively.
Additional data reported
Methods for additional data reported are detailed in the
Supplementary Appendix (Additional file 1).
Ethical approval
The research complied with the requirements of the
Declaration of Helsinki. Ethical approval was obtained
from the Newcastle and North Tyneside 1 Research Eth-
ics Committee (reference number 06/Q0905/2). Written
informed consent was obtained from participants; where
people lacked capacity to consent, for example because
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sought from a relative or carer.
Statistical analysis
NT-proBNP’s distribution was non-Gaussian, therefore
group comparisons were conducted on log transformed
data (using t-tests). Receiver Operating Characteristic (ROC)
analyses were conducted to determine NT-proBNP’s
discriminatory ability for four categories of LV dys-
function (target conditions): any grade of systolic dys-
function (LVEF≤50%); moderate/severe systolic dysfunction
(LVEF≤40%); a composite of either any grade of systolic dys-
function or isolated moderate/severe diastolic dysfunction;
and a composite of either moderate/severe systolic dys-
function or isolated moderate/severe diastolic dysfunc-
tion. Standard errors for the area under the ROC curve
(AUC) were determined using the method outlined by
DeLong et al. [18]. NT-proBNP’s performance was evalu-
ated at a range of guideline recommended and data-
derived rule-out cut points. Two data-derived rule-out
cut points were selected: ‘stringent’ with 95% sensitiv-
ity, chosen to miss few cases; and ‘optimised’, defined
as the cut point with highest sensitivity for a specificity
of at least 50%. Optimised rule-out cut points have been
proposed as a means of reducing false positives whilst still
limiting false negatives [19]. We report: sensitivity; specificity;Figure 1 Sample selection flow chart.positive predictive value (PPV); negative predictive value
(NPV); proportion of those screened at or above the cut
point i.e. in whom echocardiographic evaluation would be
warranted; and numbers of cases missed and identified,
and number of false positives, per 100 people screened.
Analyses were carried out in Stata 12.1 (StataCorp. 2011.
Stata Statistical Software: Release 12. College Station, TX:
StataCorp LP.), with statistical significance at α = 0.05.
Results
Sample selection and key characteristics
The derivation of the analysed sample (echocardiogra-
phically-characterised participants with limiting dyspnoea
and NT-proBNP data available; n=155) is shown in
Figure 1 (see also Additional file 1). Table 1 summa-
rises key demographic and clinical characteristics. The
mean (standard deviation) age of participants was 88.0
(0.5) years. Systolic dysfunction (any grade, LVEF≤50%)
was found in 34.2% (53/155) of dyspnoeic participants and
moderate/severe systolic dysfunction (LVEF≤40%) in 8.4%
(13/155); a further 19.4% (30/155) had isolated moderate/
severe diastolic dysfunction. NT-proBNP ranged from 37
to 12360ng/l; median (inter-quartile range, IQR) 406
(197-1068)ng/l. NT-proBNP levels did not differ sig-
nificantly between men and women (p-value=0.491). A
pre-existing HF diagnosis was present in 13.6% (21/155)
Table 1 Socio-demographic and clinical characteristics of
participants with limiting dyspnoea (n = 155)*
Age, mean (SD); range 88.0 (0.5);
87.0-88.9
Female 65.8 (102)
Ethnic origin- white 100 (155)
Institutional care 2.6 (4)
Heart failure 13.6 (21)
Hypertension 54.2 (84)
Ischaemic heart disease 40.0 (62)
Myocardial infarction 21.9 (34)
Cerebrovascular disease 20.0 (31)
Peripheral vascular disease 3.2 (5)
Atrial fibrillation 24.5 (38)
Diabetes Mellitus 10.3 (16)
Severe renal impairment
(estimated glomerular filtration
rate <30 ml/min/1.73 m2)
3.2 (5)
Cognitive impairment (mini-mental
state examination score ≤21)
3.9 (6)
Number of chronic diseases†, median (IQR) 5 (4-6)
Smoking Status
Current smoker 5.2 (8)
Former regular smoker 56.5 (87)
Former occasional smoker 4.6 (7)
Never smoked 33.8 (52)
Obese (BMI >30 kg/m2) 11.0 (17)
On any prescribed cardiac medications 69.7 (108)
Number of prescribed cardiovascular
medications, median (IQR)
1 (0-2)
Echocardiographically-characterised LV
dysfunction
Any grade of systolic dysfunction (LVEF≤50%) 34.2 (53)
Moderate/severe systolic dysfunction
(LVEF≤40%)
8.4 (13)
Any grade of diastolic dysfunction 87.7 (136)
Moderate/severe diastolic dysfunction 30.3 (47)
Isolated diastolic dysfunction, any grade 58.7 (91)
Isolated moderate/severe diastolic
dysfunction
19.4 (30)
NT-ProBNP, median (IQR); range (ng/l) 406 (197-1068);
37-12360
*All data are %(n) except where indicated; denominators may vary due to
missing values.
†18 diseases considered: hypertension, ischaemic heart disease,
cerebrovascular disease, peripheral vascular disease, heart failure, atrial flutter
or fibrillation, arthritis, osteoporosis, chronic obstructive pulmonary disease or
asthma, other respiratory disease, diabetes mellitus, hypothyroidism or
hyperthyroidism, cancer diagnosed within past 5 years (excluding non-melanoma
skin cancer), eye disease, dementia, Parkinson's Disease, renal impairment
and anaemia.
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high rate of false positive HF diagnosis in this population,
[14] those participants were not excluded from the ana-
lyses. To preserve generalizability to the clinical setting in
this age group where multiple conditions frequently coex-
ist, [15] participants with other potential causes of dys-
pnoea were not excluded. Significant intrinsic lung disease
by spirometric criteria (forced expiratory volume in one
second <60% of predicted value [for age, sex and height]
or forced vital capacity <70% of predicted value) was
present in 14.2% (22/155) of dyspnoeic participants. Of
note, natriuretic peptides have diagnostic utility for HF/LV
dysfunction in patients with respiratory disease [20].
Comparison of NT-proBNP level across groups defined by
LV function
Whilst there was notable overlap in NT-proBNP distri-
bution across six groups defined by LV function, all dys-
function groups had significantly higher NT-proBNP
than the group with no systolic dysfunction and no diastolic
dysfunction graded more severe than mild (Additional file 1:
Figure S1). NT-proBNP did not differ between the group
with any grade of systolic dysfunction (LVEF≤50%) and the
group with isolated moderate/severe diastolic dysfunction
(p-value=0.761).
ROC analyses
AUC for any grade of systolic dysfunction was poor
(0.58, 95% confidence interval (CI) 0.49-0.65), whilst that
for moderate/severe systolic dysfunction was good (0.80,
95% CI 0.73-0.86) (Table 2). Defining the target condi-
tion as a composite of either systolic dysfunction or iso-
lated moderate/severe diastolic dysfunction resulted in a
higher AUC for any grade of systolic dysfunction (0.64,
95% CI 0.56-0.72), but a lower AUC for moderate/severe
systolic dysfunction (0.71, 95% CI 0.63-0.78).
Table 2 details NT-proBNP’s performance for ruling
out LV dysfunction (target conditions as previously spe-
cified) using a range of guideline recommended and
data-derived rule-out cut points. For the target condition
of any grade of systolic dysfunction, the European Society
of Cardiology (ESC) guideline rule-out cut point (for non-
acute symptoms, 125ng/l) [8] missed few cases (less than
one per 100 screened, 2% of all cases; NPV 94%). How-
ever, 88% of participants had NT-proBNP at or above ESC
cut point, thereby warranting echocardiographic evalu-
ation, and the false positive rate was high (56 per 100
screened). Performance at the NICE guideline rule-out cut
point (400ng/l) [7] was poor; 45% of all cases would be
missed (16 cases missed per 100 screened; NPV 68%), al-
though - in comparison to the ESC cut point - fewer
people would require echocardiography (51%), with a
lower false positive rate (33 per 100 screened). The ESC cut
point was similar to our data-derived ‘stringent’ rule-out cut
Table 2 Diagnostic accuracy of NT-proBNP as rule-out test for LV dysfunction (types as specified)*
Prevalence of
specified LV
dysfunction
% (n)
AUC
(95% CI)
NT-proBNP cut
point (ng/l)
Sensitivity % Specificity % PPV % NPV % % of participants at
or above cut point
(echo warranted)
Number of cases
picked up per
100 screened
Number of
cases missed
per 100
screened
Number of false
positives per
100 screened
Systolic dysfunction,
any grade (LVEF≤50%)
34.2 (53) 0.58
(0.49-0.65)
ESC guideline rule-out cut
point, 125ng/l
125 98.1 14.7 37.4 93.8 87.7 33.5 0.6 56.1
NICE guideline rule-out cut
point, 400ng/l
400 54.7 50.0 36.3 68.0 51.0 18.7 15.5 32.9
Data-derived 'stringent'
rule-out cut point (closest
to 95% sensitivity)
131 96.2 16.7 37.5 89.5 87.7 32.9 1.3 54.8
Data-derived 'optimised'
rule-out cut point (highest
sensitivity with specificity
at least 50%)
380 56.6 50.0 37.0 68.9 52.3 19.3 14.8 32.9
Moderate/severe systolic
dysfunction (LVEF≤40%)
8.4 (13) 0.80
(0.73-0.86)
ESC guideline rule-out cut
point, 125ng/l
125 100.0 11.3 9.4 100.0 87.7 8.4 0.0 81.2
NICE guideline rule-out cut
point, 400ng/l
400 84.6 51.4 13.8 97.3 51.0 7.1 1.3 44.5
Data-derived 'stringent'
rule-out cut point (closest
to 95% sensitivity)
197 100.0 26.8 11.1 100.0 75.5 8.4 0.0 67.1
Data-derived 'optimised'
rule-out cut point (highest
sensitivity with specificity
at least 50%)
363 84.6 50.0 13.4 97.3 52.9 7.1 1.3 45.8
Systolic dysfunction (any
grade) OR isolated moderate/
severe diastolic dysfunction
53.5 (83) 0.64
(0.56-0.72)
ESC guideline rule-out cut
point, 125ng/l
125 95.2 16.7 56.8 75.0 87.7 50.9 2.6 38.7
NICE guideline rule-out cut
point, 400ng/l
400 60.2 58.3 62.5 56.0 51.0 32.3 21.3 19.4
Data-derived 'stringent'
rule-out cut point (closest
to 95% sensitivity)
120 95.2 16.7 56.8 75.0 89.7 50.9 2.6 38.7
Data-derived 'optimised'
rule-out cut point (highest
sensitivity with specificity
at least 50%)
319 63.9 51.4 60.2 55.2 56.8 34.2 19.4 22.6
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Table 2 Diagnostic accuracy of NT-proBNP as rule-out test for LV dysfunction (types as specified)* (Continued)
Moderate/severe systolic
dysfunction OR isolated
moderate/severe diastolic
dysfunction
27.7 (43) 0.71
(0.63-0.78)
ESC guideline rule-out cut
point, 125ng/l
125 93.0 11.6 28.8 81.3 87.7 25.8 1.9 63.9
NICE guideline rule-out cut
point, 400ng/l
400 74.4 57.1 40.0 85.3 51.0 20.6 7.1 31.0
Data-derived 'stringent'
rule-out cut point (closest
to 95% sensitivity)
113 95.3 11.6 29.3 86.7 90.3 26.5 1.3 63.9
Data-derived 'optimised'
rule-out cut point (highest
sensitivity with specificity
at least 50%)
298 79.1 50.0 37.8 86.2 58.1 21.9 5.8 36.1
*Abbreviations: AUC area under curve, PPV positive predictive value, NPV negative predictive value, ESC European Society of Cardiology, NICE National Institute for Health and Care Excellence.
Detailed legend: Diagnostic accuracy of NT-proBNP as rule-out test for LV dysfunction (types as specified) at range of guideline recommended and data-derived rule-out cut points.
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data-derived ‘optimised’ rule-out cut point (380ng/l). For
moderate/severe systolic dysfunction, at the ESC cut point
no cases would be missed (NPV 100%); however, 88% of
those screened would require echocardiography, with a false
positive rate of 81 per 100 screened. Using the NICE cut
point, one case would be missed per 100 screened (15% of
all cases; NPV 97%); in comparison to the ESC cut point,
fewer people would require echocardiography (51%), with a
lower false positive rate (45 per 100 screened). The NICE
cut point was again similar to our ‘optimised’ rule-out cut
point (363ng/l), whilst the ESC cut point was somewhat
lower than our ‘stringent’ cut point (197ng/l). We compared
NT-proBNP’s performance for the composite target condi-
tions of either systolic dysfunction (any grade or moderate/
severe) or isolated moderate/severe diastolic dysfunction to
that for the same grade of systolic dysfunction alone. Incorp-
orating diastolic dysfunction into the target condition gener-
ally increased the proportion of all cases missed (lower
NPV), whilst increasing the number of cases identified andFigure 2 Utility of ‘NT-proBNP or previous MI’ algorithm. Detailed lege
dysfunction in very old people with limiting dyspnoea.decreasing the false positive rate (see Additional file 1:
Supplementary Appendix).
We also examined test performance at two confirma-
tory or rule-in cut points (Additional file 1: Table S2).
Incorporating previous MI history and NT-proBNP in risk
assessment
The NICE Chronic HF Diagnostic Algorithm (for use when
HF is clinically suspected) recommends that individuals
with a previous MI should be referred directly for echocar-
diographic evaluation, without preliminary natriuretic pep-
tide measurement; those without previous MI should be
referred on the basis of natriuretic peptide level [7]. We ex-
amined the algorithm’s utility for excluding LV dysfunction
in our sample of very old people with limiting dyspnoea,
and compared it to a strategy using NT-proBNP alone.
Figure 2 presents data for the algorithm using NT-
proBNP or previous MI and Figure 3 the equivalent data
for the strategy using NT-proBNP alone; Table 3 summa-
rises diagnostic accuracy. Out of our participants withnd: Utility of ‘NT-proBNP or previous MI’ algorithm for ruling out LV
Figure 3 Utility of NT-proBNP alone. Detailed legend: Utility of NT-proBNP alone for ruling out LV dysfunction in very old people with limiting
dyspnoea.
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comparison to using NT-proBNP alone, incorporating MI
history resulted in modest increases in both the propor-
tion requiring echocardiography (51% for NT-proBNP
level alone versus 59% with MI incorporated) and false
positive rates. The effect on the number of cases missed/
identified depended on the target condition. For any grade
of systolic dysfunction and the two composite conditions
of either systolic dysfunction (any grade or moderate/se-
vere) or isolated moderate/severe diastolic dysfunction, in-
corporating MI history slightly improved performance. In
contrast, for moderate/severe systolic dysfunction the
numbers of cases missed/identified remained the same.
Discussion
We report novel data on the utility of NT-proBNP, alone
and in combination with MI history, as a rule-out test
for LV systolic and diastolic dysfunction in very old people
with limiting dyspnoea. The rule-out cut points recom-
mended by the ESC (125ng/l) [8] and NICE (400ng/l) [7]guidelines differ widely, and we show that both have limi-
tations in this age group. Focusing on NT-proBNP’s ability
as a rule-out test for LV systolic dysfunction, applying the
ESC cut point resulted in very few cases being missed;
however, 88% of very old people with limiting dyspnoea
had NT-proBNP at or above this cut point, thereby war-
ranting echocardiography, with high false positive rates.
Using the higher NICE cut point, echocardiography and
false positive rates would be lower, although still substan-
tial; however, whilst exclusionary performance was good
for moderate/severe systolic dysfunction it was poor for
any grade of systolic dysfunction (45% of cases missed).
LVEF between 40-50% is much commoner than ≤40%
(prevalence 26% and 8% respectively in our sample), and
associated with prevalent and incident HF and mortality;
[21] it is therefore important to identify less severe forms
of dysfunction and prevent/delay their progression to
more severe dysfunction and overt HF [3]. Incorporating
isolated moderate/severe diastolic dysfunction (19% of our
sample) into the target condition, generally increased the
Table 3 Diagnostic accuracy of NT-proBNP alone and 'NT-proBNP or previous MI' algorithm*
Sensitivity % Specificity % PPV % NPV % % of people screened
requiring echo
Number of cases picked
up per 100 screened
Number of cases
missed per 100
screened
Number of false
positives per 100
screened
Systolic dysfunction, any grade
(LVEF≤50%)
NT-pro BNP alone (refer for
echocardiography if ≥400ng/l)
54.7 50.0 36.3 68.0 51.0 18.7 15.5 32.9
‘NT-proBNP or previous MI' algorithm
(refer for echocardiography if prior MI
or NT-pro BNP ≥400ng/l)
64.2 44.1 37.4 70.3 58.7 21.9 12.3 36.8
Moderate/severe systolic dysfunction
(LVEF≤40%)
NT-pro BNP alone (refer for
echocardiography if ≥400ng/l)
84.6 51.4 13.8 97.3 51.0 7.1 1.3 44.5
‘NT-proBNP or previous MI' algorithm
(refer for echocardiography if prior MI
or NT-pro BNP ≥400ng/l)
84.6 43.7 12.1 96.9 58.7 7.1 1.3 51.6
Systolic dysfunction (any grade) OR
isolated moderate/severe diastolic
dysfunction
NT-pro BNP alone (refer for
echocardiography if ≥400ng/l)
60.2 58.3 62.5 56.0 51.0 32.3 21.3 19.4
‘NT-proBNP or previous MI' algorithm
(refer for echocardiography if prior MI
or NT-pro BNP ≥400ng/l)
67.5 51.4 61.5 57.8 58.7 36.1 17.4 22.6
Moderate/severe systolic dysfunction
OR isolated moderate/severe diastolic
dysfunction
NT-pro BNP alone (refer for
echocardiography if ≥400ng/l)
74.4 57.1 40.0 85.3 51.0 20.6 7.1 31.0
‘NT-proBNP or previous MI' algorithm
(refer for echocardiography if prior MI
or NT-pro BNP ≥400ng/l)
76.7 48.2 36.3 84.4 58.7 21.3 6.5 37.4
Detailed legend: Diagnostic accuracy of 'NT-proBNP or previous MI' algorithm as rule-out test for LV dysfunction (types as specified); comparison with strategy using NT-proBNP alone.
*Abbreviations: PPV positive predictive value, NPV negative predictive value.
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the number of cases identified and decreasing the false
positive rate, when compared with NT-proBNP’s perform-
ance for the same severity of systolic dysfunction alone.
Although no therapy has proved effective in preventing
progression of diastolic dysfunction to HF-PEF, or in im-
proving outcomes in established HF-PEF, [8] it is import-
ant to diagnose it accurately and instigate appropriate
management [22].
Through comparison with our data-derived cut points,
it appears that the ESC cut point is generally an appro-
priate ‘stringent’ rule-out cut point (misses few cases) in
the very old, whilst the NICE cut point is an appropriate
‘optimised’ rule-out cut point (cuts down false positives
whilst still limiting false negatives). However, whilst
these may be the most appropriate cut points for this
age group, their performance metrics limit their overall
utility. Interestingly, the NICE cut point has been criticised
as being too high, with lower age-specific optimised rule-
out cut points recommended (for NT-proBNP: <50 years,
50ng/l; 50-75 years, 75ng/l; age 75+, 223ng/l); [19] our data
suggests that the NICE cut point is the appropriate
optimised cut point for 87-89 year olds.
NT-proBNP’s limited diagnostic accuracy for LV dys-
function in the very old is likely to reflect the high
prevalence of other cardiac and non-cardiac morbidities
known to elevate natriuretic peptides, [11] compounded
by the high consumption of medications (for co-morbid
conditions such as hypertension) which can potentially
lower peptides below threshold levels even in the pres-
ence of LV dysfunction [7]. Including MI history as an
additional referral prompt (as per NICE Chronic HF
Diagnostic Algorithm [7]) was of no overall benefit. It
resulted in, at best, only a slight drop in cases missed
(and no change for moderate/severe systolic dysfunc-
tion), at the expense of higher echocardiography and
false positive rates.
Few studies have examined the diagnostic accuracy of
natriuretic peptides in older people, [23] with the 85+
age group particularly under-investigated. Study setting
(population-based, primary care, care home, emergency
department, out-patient department etc.) affects preva-
lence and severity of LV dysfunction/HF and consequently
test performance, and it is not possible to extrapolate find-
ings directly from one setting to another. Our study is
among the first in the very old to incorporate detailed
home-based assessment of LV function with natriuretic
peptide measurement, and to our knowledge is the largest
population-based study of very old people with a clinical
suspicion of chronic HF. Only two previous studies have
focused on the symptomatic very old, both concluding
that whilst natriuretic peptides have some utility as rule-
out tests their performance metrics are inferior compared
to younger age groups [24,25]. Olofsson et al. examined asample with symptoms/signs suggestive of HF from a sin-
gle primary care centre (estimated n=67 aged 80+), with
the emphasis on detecting systolic HF [24]. Chenevier-
Gobeaux et al. investigated emergency department at-
tendees with acute dyspnoea (n=210, aged 85+); [25] in
acute studies, higher threshold natriuretic peptide values
are observed in comparison to chronic dyspnoea [19]. The
utility of HF diagnostic algorithms was examined by
Oudejans et al. in geriatric out-patients with a clinical sus-
picion of new slow onset HF (n=206, aged 70-98) [26].
The performance of the NICE algorithm was superior to
that found in our study, which may reflect the different
target conditions studied; Oudejans et al. focused on clin-
ical HF in contrast to our study of LV dysfunction in
which natriuretic peptide performance is known to be
poorer [9]. Like us, Oudejans et al. concluded that the per-
formance of NT-proBNP alone was superior to algorithms
additionally incorporating MI history.
Strengths of this study are its population-based sam-
ple, including the institutionalised and cognitively im-
paired, and its domiciliary echocardiographic approach
incorporating assessment of both systolic and diastolic
dysfunction. Hospital-based assessment of this age group
is known to introduce selection bias [27]. A limitation is
our use of LV dysfunction as the target condition rather
than clinical HF; full clinical assessment for HF was not
possible within the scope of this study. However, our
focus on the use of natriuretic peptides to rule out LV
dysfunction in a sample with a clinical suspicion of HF
is in accordance with other important work in the field
[19,28-33]. A potential limitation is our use of limiting
dyspnoea without clinical examination to define a sam-
ple with a suspicion of HF, although classical physical
signs such as basal crepitations and oedema are known
to lack both sensitivity and specificity in this age group
[9]. Dyspnoea has a high sensitivity (89%) for chronic HF,
although low specificity (51%) [9]. We did not exclude
participants with other potential causes of dyspnoea as we
were interested in NT-proBNP’s performance in a ‘real life’
unselected sample of dyspnoeic very old people. Further-
more, the co-existence of multiple morbidities is common
in this age group [15]. Clearly the full diagnostic work-up
of dyspnoeic patients should include consideration of
non-cardiac conditions. The practical considerations of
performing domiciliary echocardiography with a handheld
instrument meant that data for some measurements was
more incomplete than might have been achieved in a hos-
pital setting [14].
Conclusions
High echocardiography rates and poor exclusionary per-
formance for mild degrees of systolic dysfunction and
for diastolic dysfunction limit NT-proBNP’s utility as a
rule-out test for LV dysfunction in very old people with
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http://www.biomedcentral.com/1471-2261/14/128limiting dyspnoea. Therefore alternative strategies merit
consideration. These might include other blood-based
biomarkers, either singly or in combination panels, al-
though a recent study in a care home population found
the novel biomarkers copeptin, MR-proADM and MR-
proANP to have little diagnostic utility in older people
with significant co-morbidity [34]. Clinical decision rules,
combining natriuretic peptide measurement with add-
itional variables (symptoms, signs and test results), have
been proposed although the optimal approach and cost-
effectiveness are uncertain [35]. Atypical HF presentations
in the very old, [4] coupled with high levels of non-
specific ECG findings and co-morbidity, [2] may limit
the utility of such approaches in this age group. Opti-
mal evaluation of this age group may require direct ac-
cess to echocardiography without preliminary peptide
measurement, an approach which has recently been
advocated for older people with medium/high prob-
ability of HF [22]. Whilst cost-effectiveness needs to be
determined, it merits further evaluation given the high
costs of HF to healthcare providers [36] and rapid ex-
pansion of the very old population [1]. If this strategy
were adopted, our findings imply that substantially in-
creased echocardiography provision, in accessible settings,
would be required. Community-based echocardiography
services, including the option of home-based assessment,
might best meet the needs of this often frail and multi-
morbid group.
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